1. Introduction {#sec1}
===============

A new Coronavirus SARS-CoV-2 (COVID-19) has been identified as the cause of Severe Acute Respiratory Syndrome (SARS), a severe form of viral pneumonia associated with high mortality. This virus spread from China to the rest of the world into a real short period and with an important severity, leading the World Health Organization (WHO) to consider a "global emergency".

SARS-CoV-2 is a RNA virus sharing about 80% of the viral genome with SARS-CoV (responsible for the 2003 outbreak) ([@bib26]).

Several studies confirmed that the virus is able to penetrate into human cells by binding to ACE-2 protein, the angiotensin-converting enzyme 2, which is part of the renin-angiotensin system (RAS) ([@bib11]) and considered as a possible membrane receptor. It has also been noted that patients infected by this virus, during the sick days, have functional variations in the concentrations of enzymes components of the RAS ([@bib13]; [@bib30]). This is a defense mechanism of the human host that helps against the infection or is responsible for a worsening of clinic?al conditions and, as consequence, to be corrected pharmacologically? ([@bib12])

2. The correlation between RAS and SARS-CoV-2 {#sec2}
=============================================

The renin-angiotensin system (RAS) is a physiological mechanism able to regulate different functions of the body, in particular the most important are the regulation of blood pressure, the volume of circulating plasma (volemia) and the tone of the arterial muscles through different mechanisms. RAS is an enzymatic cascade; the main enzyme pathway (classical) is renin which converts the angiotensinogen, released by the liver, into angiotensin I (Ang I). Ang I is subsequently converted to angiotensin II (Ang II) by the angiotensin-converting enzyme (ACE). There is also another (non-classical) enzyme pathway, mediated by ACE-2 ([@bib1]), in this pathway ACE-2 converts Ang II to angiotensin 1-7 (Ang 1--7) and Ang I to angiotensin 1-9 (Ang 1--9).

ACE-2 is a type I membrane metallocarboxypeptidase with high ACE homology, the functions are distinct and the two enzymes are also expressed differently in tissues. For example, ACE-2 is most expressed in renal, cardiovascular, pulmonary and gastrointestinal tissues, ACE activity is highly expressed in the lungs, brain and kidneys ([@bib20]). Some aspects on the correlation between the various stages of SARS-CoV-2 infection and the RAS variation remain to be clarified. SARS-CoV-2 infection has been divided into three phases: the first asymptomatic or slightly symptomatic, the second and the third more severe, characterized by hyperinflammatory state. In the second and third phase it seems that the worst damage is caused by a generalized inflammatory state, caused by a "cytokine storm" and responsible for severe lung injury and multi-organ dysfunction ([@bib25]).

Several studies have shown that variation in the RAS can be very related to SARS-CoV-2 infection, and involved in all stages.

ACE-2 has been identified as an input membrane receptor for SARS-CoV-2 in epithelial lung cells; this evidence may suggest that increased expression of ACE-2 is related to an increased risk of SARS-CoV-2 infection.

In addition, as described above, variations in RAS were noted during the various stages of SARS-CoV-2 infection; in particular, the evidence showed increased activation of the system in the early stages, and then decreased in subsequent stages, although the data showing these variations are conflicting and not entirely clear ([@bib29]; [@bib7]). Certainly, the activation of RAS is known to change in conditions such as COPD, asthma, during viral infections and in smokers, demonstrating that the system is related to correct lung and airway function. The evidence suggests that the physiological balance of the RAS system and especially between ACE/ACE-2 is likely to be altered by SARS-CoV-2 viral infection. This RAS imbalance is likely to play a role in lung lesion and inflammatory state activation, but these aspects have yet to be clarified. In this direction, the pharmacological approach to regulated the concentration of ACE/ACE-2 could be a way to moderate severe lung damage virus-induced ([@bib2]; [@bib8]). In addition, ACE-2 has been shown to play a role in fibrogenesis and inflammation of different organs, including the lungs. Studies in patients infected with SARS-CoV-2 showed that ACE-2 expression has a rapid increase in the first hours of viral infection, then begins rapid down-regulation in the lung tissue when the patient enters stage two and three of the infection. However, it can be possible that ACE-2 has a protective effect and when it decreases there is a worsening of the lungs inflammatory state. In addition, specific studies show that ACE-2 expression is decreased in respiratory diseases, such as pulmonary fibrosis or COPD. It should also be noted that Ang II, Ang 1--7 and Ang 1--9 have different biological effects. In fact, the biological effects of Ang II are vasoconstrictor and aldosterone release stimulant; but can cause also myocardial hypertrophy, interstitial fibrosis, endothelial dysfunction, increase of inflammation state, oxidative stress and increased of coagulation, biological effects that, if altered, can cause serious complications in a patient with SARS-CoV-2 infection ([@bib28]). Ang II can cause increased inflammation through production of IL-6, TNF (Tumor Necrosis Factor) and other inflammatory cytokines ([@bib22]; [@bib27]; [@bib16]).

However, it is important to note that all these biological effects are mediated by AT-1 receptors (AT-1r). ACE-2 can reduce the negative effects of Ang II through several mechanisms, for example by the conversion of Ang II to Ang 1--7. Ang1-7 has opposite biological effects to Ang II through the Mas receptor (MASr) and Type II receptors of Ang II (AT-2r). The MASr are expressed on the surface of bronchial muscle and alveolar epithelium of the lungs ([@bib17]), and the Ang 1--7 has anti-inflammatory and antifibrosis effects by MASr agonist effect ([@bib4]; [@bib19]).

In addition, MASr are expressed on platelets, and Ang 1--7 mediates the antiaggregant effects ([@bib6]; [@bib21]; [@bib9]) because it is able to increase prostacyclines ([@bib10]). This description suggest that pharmacological modulation of RAS at different stages of SARS-CoV-2 infection could be a beneficial and effective therapy.

3. The pharmacological approach by modulating RAS in SARS-CoV-2 infection {#sec3}
=========================================================================

A pharmacological approach modulating RAS could be of clinical benefit to fight SARS-CoV-2 infection. Agents acting on RAS can be distinguished as angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs) ([@bib3]).

These agents are currently indicated for the treatment of various cardiovascular diseases with excellent clinical efficacy. ACEIs are able to reduce blood pressure by acting with ACE inhibition which converts Ang I to Ang II. ARBs are Ang II antagonists on the type 1 receptor (AT-1r), finally, DRIs block plasma renin activity and inhibit the conversion of angiotensinogen to Ang I. The three different classes described above have different effects on the regulation and enzymatic expression of RAS. In fact, on the basis of *in vitro* studies, it seems that the use of ACEIs, with a blockade of the enzyme ACE, increases the expression of the enzyme ACE-2 (stimulating other synthesis pathways), although these data are not fully confirmed and at the moment very contradictory ([@bib24]). The use of ARBs seems to be linked to a slight increase in the expression of both ACE and ACE-2. Finally, the use of DRIs, by inhibiting the upstream RAS cascade, seems to inhibit expression and consequently decrease ACE and ACE-2 concentrations. This shows that there are available agents able to act with a different modulation of RAS expression and its components. These evidences suggest that RAS could be modulated with a pharmacological approach to avoid complications of viral infection. There is a scientific debate (still ongoing) for several months as to whether increased ACE-2 using ACEIs or ARBs could be a risk factor for COVID-19 infection, at the moment epidemiological data do not show any correlation between the use of ACEIs or ARBs and increased likelihood of infection or complications of SARS-CoV-2. However, an increase in ACE-2 in the more severe stages of viral infection could be beneficial. An increase in ACE-2 synthesizes more Ang 1--7 and Ang-1-9 with vasodilating, antinfiammatory and antifibrotic properties ([@bib23]; [@bib14]). In addition, the use of ARBs, increases the stimulation of AT-2r by Ang II, with vasodilating antifibrotic and antioxidant effects.

In conclusion, there is currently no evidence which demonstrate that the use of ACEIs or ARBs should be discontinued in treated patients, because they do not represent a risk factor that increases the likelihood of SARS-CoV-2 infection ([@bib18]), however it has been shown that the activation of the Ang II-AT-1r axis can promote lung damage, while increasing ACE-2 and activating the Ang 1--7/MASr axis may protect against lung damage ([@bib15]; [@bib5]). RAS modulating agents may be beneficial in combating SARS-CoV-2 infection, clinical studies are necessary to confirm these hypotheses.

4. Suggestions {#sec4}
==============

More extensive epidemiological studies should be designed to investigate the real correlation between RAS and COVID-19, in particular to clarify whether an increase of ACE-2 with ACEis or ARBs can be considered an important risk factor of SARS-CoV-2 infection, and whether an increase of ACE-2 in the most severe stages of infection can play a protective role, we believe based on current evidence in the literature that modulating the RAS system at the right time and correctly could be of enormous clinical benefit to avoid serious complications from COVID-19.

Main statements {#sec5}
===============

I, The undersigned, Francesco Ferrara and any other author, declare that:

We have no conflict of interest;

We have not received funding;

There are no sensitive data and no patients were recruited for this study;

The document does not conflict with ethical legislation.

All authors read and approved the final manuscript.

Founds {#sec6}
======

None.

Copyright {#sec7}
=========

The authors certify that the manuscript is original, never submitted to other journal for publication before. All authors contributed equally to the manuscript and had the opportunity to revise and approve the final text.

Disclosure statement {#sec8}
====================

Dr. A. Vitiello has nothing to disclose.

Dr. F. Ferrara has nothing to disclose.

CRediT authorship contribution statement {#sec9}
========================================

**Antonio Vitiello:** Conceptualization, Writing - original draft, Methodology, Writing - original draft. **Francesco Ferrara:** Writing - review & editing, Supervision, Validation.

Declaration of competing interest
=================================

None of the Authors have conflicts of interest to disclose.
